Payment overview · 2025
General Payments
$633.41
34 reported records · 13 companies
Healthcare provider profile · identity verified
Barbara Ann Kish, CFNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SAGINAW, MI · NPI 1902894769
Verified facts
What the public records show
CMS Open Payments records show Barbara Ann Kish, CFNP received $633.41 in general payments during 2025 across 34 reported records.
Gilead Sciences, Inc. accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $183.34 | 28.9% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.86 | 14.0% | 6 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $72.90 | 11.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $57.19 | 9.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.01 | 7.4% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $46.03 | 7.3% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.70 | 3.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.05 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.53 | 3.4% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $20.56 | 3.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.65 | 2.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.80 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.79 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $633.41 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $88.86 | 6 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $57.19 | 3 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $46.03 | 3 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $45.40 | 2 | 2025 |
Source payment records
|
|||||
| DELSTRIGO Normalized: delstrigo |
Drug | Merck Sharp & Dohme LLC | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.64 | 2 | 2025 |
Source payment records
|
|||||
| NUVARING Normalized: nuvaring |
Drug | Organon LLC | $29.37 | 2 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 347 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 187 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 170 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 165 | 38 |
| Lisinopril | Lisinopril | 137 | 44 |
| Losartan Potassium | Losartan Potassium | 122 | 32 |
| Tramadol Hcl | Tramadol Hcl | 120 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 39 |
| Famotidine | Famotidine | 117 | 33 |
| Metformin Hcl | Metformin Hcl | 116 | 35 |
| Potassium Chloride | Potassium Chloride | 107 | 26 |
| Furosemide | Furosemide | 97 | 25 |
| Gabapentin | Gabapentin | 88 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 20 |
| Jardiance | Empagliflozin | 75 | 28 |
| Omeprazole | Omeprazole | 69 | 28 |
| Ozempic | Semaglutide | 69 | 12 |
| Alendronate Sodium | Alendronate Sodium | 68 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 24 |
| Prednisone | Prednisone | 62 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 26 |
| Meloxicam | Meloxicam | 53 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 47 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 43 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 11 |
| Ibuprofen | Ibuprofen | 42 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 38 | 11 |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 32 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 20 |
| Eliquis | Apixaban | 29 | suppressed |
| Clotrimazole | Clotrimazole | 28 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Arnuity Ellipta | Fluticasone Furoate | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Glipizide | Glipizide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Cephalexin | Cephalexin | 18 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Flunisolide | Flunisolide | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 15 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 11 |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Havrix | Hepatitis A Virus Vaccine/Pf | 14 | 13 |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $633.41 · 34 records | Gilead Sciences, Inc. | AIRSUPRA, APRETUDE, Biktarvy, CAPVAXIVE, Cologuard Collection Kit, DELSTRIGO, DOVATO, Epclusa, FANAPT, FARXIGA, GVOKE HYPOPEN, MAVYRET, NEXPLANON, NUVARING, Natroba, Ozempic, PIFELTRO, Rybelsus, SPRAVATO, Spinosad, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error